Sequential Changes in Plasma Fibronectin in Patients with Subarachnoid Hemorrhage

Shiro KASHIWAGI, Yujiro SHIROYAMA, Tetsuaki IWAMOTO, Tetsuo YAMASHITA and Haruhide ITO

Department of Neurosurgery, Yamaguchi University School of Medicine, Ube, Yamaguchi

Abstract

Sequential changes in plasma fibronectin level in 17 patients with subarachnoid hemorrhage (SAH), with 16 due to ruptured cerebral aneurysms, were compared for patients with good and poor outcomes, and patients with and without vasospasm. Plasma fibronectin concentrations were measured by an immune diffusion method. The clinical outcome was evaluated 3 months after SAH according to the Glasgow Outcome Scale. Plasma fibronectin concentrations were significantly lower on days 3 (p < 0.02) and 9 (p < 0.05) after ictus in patients with poor outcomes (moderately disabled or worse) than in those with good outcomes (good recovery). Patients with vasospasm had lower fibronectin concentrations during the 4 weeks after ictus. Decreased levels of plasma fibronectin were correlated with poor outcomes, most related to vasospasm. Plasma fibronectin levels reflect the overall severity in patients with SAH and are a useful marker for prediction of the final clinical outcome.

Key words: fibronectin, outcome, subarachnoid hemorrhage, vasospasm

Introduction

Cerebral vasospasm and rebleeding are two major causes of death and disability after subarachnoid hemorrhage (SAH) due to a ruptured cerebral aneurysm. Once the aneurysm has been clipped successfully, the severity of the vasospasm becomes one of the main factors determining the outcome. However, no single hematological marker can predict the occurrence of vasospasm.

Fibronectin is a high molecular weight glycoprotein found in a soluble form in the blood and in an insoluble form in connective tissues, and associated with basement membranes. It interacts with collagen, fibrin, and other components of hemostatic and fibrinolytic systems. Since endothelial damage, coagulopathy, complement-activating immune complexes are involved in the process underlying vasospasm, the plasma fibronectin concentration may reflect the severity of the disease and be correlated with the final outcome.

This study measured the sequential changes in plasma fibronectin level in patients with SAH, and investigated correlation with the final clinical outcome and occurrence of symptomatic cerebral vasospasm.

Materials and Methods

Table 1 summarizes the clinical data for the 17 patients in this study. There were eight females and nine males, ranging in age from 43 to 78 years (mean, 62.2 yrs). Sixteen patients presented with SAH due to ruptured cerebral aneurysms and one with SAH of unknown origin. Clinical status on admission was determined by the Hunt and Kosnik scale, and the severity of SAH on admission by the Fisher computed tomographic (CT) scale. Fifteen patients were operated on to clip ruptured aneurysms. Symptomatic vasospasm was defined clinically as delayed neurological deterioration including disturbed consciousness and a focal neurological deficit with CT evidence of local ischemia. Neurological deterioration due to hydrocephalus or rebleeding was excluded by CT. The outcome was assessed 3 months after ictus according to the Glasgow Outcome Scale (GOS). Blood samples were collected on days 1, 3, 5, 7, 9,
Table 1 Summary of the 17 patients in this study

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age/Sex</th>
<th>Location of aneurysm</th>
<th>Clinical grade*</th>
<th>Severity of SAH**</th>
<th>Timing of operation</th>
<th>Vasospasm</th>
<th>Outcome***</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>57/F</td>
<td>lt MCA</td>
<td>I</td>
<td>2</td>
<td>EO</td>
<td>-</td>
<td>GR</td>
</tr>
<tr>
<td>2</td>
<td>63/F</td>
<td>rt MCA</td>
<td>II</td>
<td>3</td>
<td>EO</td>
<td>-</td>
<td>GR</td>
</tr>
<tr>
<td>3</td>
<td>63/F</td>
<td>none</td>
<td>II</td>
<td>3</td>
<td>not done</td>
<td>-</td>
<td>GR</td>
</tr>
<tr>
<td>4</td>
<td>75/F</td>
<td>lt IC-PComA</td>
<td>II</td>
<td>3</td>
<td>EO</td>
<td>+</td>
<td>GR</td>
</tr>
<tr>
<td>5</td>
<td>50/M</td>
<td>AComA</td>
<td>II</td>
<td>2</td>
<td>EO</td>
<td>-</td>
<td>GR</td>
</tr>
<tr>
<td>6</td>
<td>43/M</td>
<td>AComA</td>
<td>II</td>
<td>3</td>
<td>DO</td>
<td>-</td>
<td>MD</td>
</tr>
<tr>
<td>7</td>
<td>73/M</td>
<td>AComA</td>
<td>II</td>
<td>2</td>
<td>DO</td>
<td>+</td>
<td>MD</td>
</tr>
<tr>
<td>8</td>
<td>59/M</td>
<td>rt MCA</td>
<td>II</td>
<td>3</td>
<td>EO</td>
<td>+</td>
<td>MD</td>
</tr>
<tr>
<td>9</td>
<td>58/F</td>
<td>lt PCA</td>
<td>III</td>
<td>3</td>
<td>DO</td>
<td>+</td>
<td>GR</td>
</tr>
<tr>
<td>10</td>
<td>53/M</td>
<td>AComA</td>
<td>III</td>
<td>3</td>
<td>EO</td>
<td>+</td>
<td>GR</td>
</tr>
<tr>
<td>11</td>
<td>63/M</td>
<td>rt IC-AChA</td>
<td>III</td>
<td>3</td>
<td>EO</td>
<td>-</td>
<td>MD</td>
</tr>
<tr>
<td>12</td>
<td>57/M</td>
<td>rt PCA</td>
<td>III</td>
<td>3</td>
<td>DO</td>
<td>-</td>
<td>MD</td>
</tr>
<tr>
<td>13</td>
<td>63/F</td>
<td>rt MCA</td>
<td>III</td>
<td>3</td>
<td>EO</td>
<td>-</td>
<td>MD</td>
</tr>
<tr>
<td>14</td>
<td>62/F</td>
<td>AComA</td>
<td>III</td>
<td>4</td>
<td>EO</td>
<td>+</td>
<td>MD</td>
</tr>
<tr>
<td>15</td>
<td>78/M</td>
<td>rt MCA</td>
<td>III</td>
<td>3</td>
<td>DO</td>
<td>+</td>
<td>SD</td>
</tr>
<tr>
<td>16</td>
<td>68/M</td>
<td>AComA</td>
<td>III</td>
<td>4</td>
<td>EO</td>
<td>+</td>
<td>D</td>
</tr>
<tr>
<td>17</td>
<td>73/F</td>
<td>unverified</td>
<td>III</td>
<td>3</td>
<td>not done</td>
<td>+</td>
<td>D</td>
</tr>
</tbody>
</table>


Results

The clinical outcome was good (good recovery) in seven patients and poor (moderately disabled, severely disabled, and died) in 10 (Table 1). Figure 1 shows the sequential changes in fibronectin concentrations in patients with good and poor outcomes. The poor outcome group had lower fibronectin concentrations during the 1st week, with statistically significant differences on days 3 (p < 0.02) and 9 (p < 0.05).

Symptomatic vasospasm occurred in 10 patients (Table 1). Figure 2 shows sequential changes in fibronectin concentrations in patients with and without vasospasm. Patients with vasospasm had lower concentrations throughout the 4-week monitoring period, especially after day 5, although the differences were not statistically significant.

Statistically significant (p < 0.05) decreases in platelet count and increases in D-dimer and PIC values were observed in patients with vasospasm.

Fig. 1 Sequential changes in plasma fibronectin concentrations in patients with good (open circles) and poor outcomes (closed circles). The poor outcome group had lower fibronectin concentrations during the 1st week, the differences being statistically significant on days 3 and 9 (*p < 0.02, **p < 0.05).
Sequential changes in plasma fibronectin concentrations in patients with (closed circles) and without vasospasm (open circles). The patients with vasospasm had lower concentrations during the 4 weeks after ictus, especially after day 5. The differences were not statistically significant.

Discussion

Plasma fibronectin levels decrease in patients following major surgery or major trauma, and in severely ill patients with evidence of disseminated intravascular coagulation.\(^{21-23}\) The concentration of plasma fibronectin required for normal function is unknown, but patients with less than 50% of the normal concentration had a higher mortality than those with normal concentrations.\(^{16,23}\) Non-surviving trauma patients demonstrate a persistent depletion of plasma fibronectin, while survivors with equally severe injuries show early restoration of the normal level after trauma.\(^{23}\)

Since rebleeding caused clinical deterioration in none of our patients, cerebral vasospasms were regarded as the major cause of mortality and disability. The plasma fibronectin concentrations were lower in patients with symptomatic vasospasm than those without. A condition similar to disseminated intravascular coagulation occurs in patients with vasospasm due to endothelial damage in the cerebral arteries.\(^{2,5,26,27}\) The hematological markers in our patients, such as platelet counts, FDP, D-dimer, and PIC values, suggested that intravascular coagulation was associated with the decreased plasma fibronectin levels. Therefore, the depletion of plasma fibronectin resulted from deposition of fibronectin in thrombi, binding to areas of tissue injury due to its high affinity for damaged tissue, and utilization as a nonspecific opsonin in the reticuloendothelial disposal of circulating fibrin complexes.\(^{20,30}\)

Persistent depletion of plasma fibronectin may induce detachment of vascular endothelial cells because the plasma fibronectin pool may contribute to the cell surface fibronectin pool, which is important in the adhesion of endothelial cells to the subendothelium. This could aggravate the process of vasospasm and may also impair the healing of damaged tissue.

Our study indicated that a decreased level of plasma fibronectin during the 1st week after SAH was related to a poor outcome at 3 months, and that patients with symptomatic vasospasm tended to have lower levels of plasma fibronectin during the 4 weeks after SAH. These results suggested that the plasma fibronectin concentration reflects the overall severity in patients with SAH, and is a useful prognostic marker for the final outcome.

References

2. Ettinger MG: Coagulation abnormalities in subarachnoid hemorrhage. Stroke 1: 139-142, 1970

Address reprint requests to: S. Kashiwagi, M.D., Department of Neurosurgery, Yamaguchi University School of Medicine, 1144 Kogushi, Ube, Yamaguchi 755, Japan.